HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

Journal of Clinical Investigation

Volumn 104, Issue 6, 1999, Pages

  Ortiz, Gabriel M ^a   Nixon, Douglas F ^a,b   Trkola, Alexandra ^a   Binley, James ^a   Jin, Xia ^a   Bonhoeffer, Sebastian ^a   Kuebler, Peter J ^a   Donahoe, Sean M ^a   Demoitie, Marie Ange ^a   Kakimoto, William M ^a   Ketas, Tom ^a   Clas, Brian ^a   Heymann, Jonas J ^a   Zhang, Linqi ^a   Cao, Yunzhen ^a   Hurley, Arlene ^a   Moore, John P ^a   Ho, David D ^a   Markowitz, Martin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS ANTIBODY; VIRUS RNA; ZIDOVUDINE;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0032719664     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7371     Document Type: Article

References (32)

1. Mellors, J., et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1167-1170.
2. O'Brien, T., et al. 1996. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 276:105-110.
3. Chun, T., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
4. Wong, J., et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1291-1295.
5. Finzi, D., et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-1300.
6. Zhang, L., et al. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
7. Finzi, D., et al. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
8. Stephenson, J. 1999. AIDS researchers target poor adherence. JAMA. 281:1069.
9. Stephenson, J. 1998. Studies reveal early impact of HIV infection, effects of treatment. JAMA. 279:641-642.
10. Arya, S. 1998. Antiretroviral therapy in countries with low health expenditure. Lancet. 351:1433-1434.
11. Markowitz, M., et al. 1999. The effect of commencing antiretroviral therapy soon after HIV-1 infection on viral replication and antiviral immune responses. J Infect. Dis. 179:525-537.
12. Jin, X., et al. 1998. Longitudinal and cross-sectional analysis of CTL responses and their relationship to vertical HIV transmission. J. Infect. Dis. 178:1317-1326.
13. Larsson, M., et al. 1999. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS. 13:767-777.
14. Nixon, D.F., et al. 1999. Molecular tracking of an HIV-1 nef specific CTL clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunol. Lett. 66:219-228.
15. Cao, Y., Qin, L., Zhang, L., Safrit, J., and Ho, D. 1996. Characterization of long-term survivors of HIV-1 infection. Immunol. Lett. 51:7-13.
16. Purtscher, M., et al. 1996. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2FS. AIDS. 10:587-593.
17. Morris, L., et al. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188:233-245.
18. Connor, R., et al. 1998. Immunological and virological analyses of persons infected by HIV-1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
19. Jubault, V., et al. 1998. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. AIDS. 12:2358-2359
20. Staszewski, S., et al. 1998. Rebound of HIV-1 viral load after suppression to very low levels. AIDS. 12:2360.
21. Vila, J., et al. 1997. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet. 350:635-636.
22. Lisziewicz, J., Jessen, H., Finzi, D., Siliciano, R., and Lori, F. 1998. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet. 352:199-200.
23. Koup, R., et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary HIV-1 syndrome. J. Virol. 68:4650-4655.
24. Borrow, P., Lewicki, H., Hahn, B., Shaw, G., and Oldstone, M. 1994. Virus-specific CD8+ CTL activity associated with control of viremia in primary HIV-1 infection. J. Virol. 68:6103-6110.
25. Borrow, P., et al. 1997. Antiviral pressure exerted by HIV-1-specific CTL during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
26. Ogg, G., et al. 1998. Quantitation of HIV-1-specific CTL and plasma load of viral RNA. Science. 279:2103-2106.
27. Ogg, G., et al. 1999. Decay kinetics of HIV-specific effector CTL after combination antiretroviral therapy. J. Virol. 73:797-800.
28. Gray, C., et al. 1999. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy. J. Immunol. 162:1780-1788.
29. Furtado, M., et al. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:1614-1622.
30. Price, D., et al. 1997. Positive selection of HIV-1 CTL escape variants during primary infection. Proc. Natl. Acad. Sci. USA. 94:1890-1895.
31. Rosenberg, E., et al. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1447-1450.
32. Zajac, A., et al. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.